> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Merck Scraps Nemtabrutinib Development After Risk-Benefit Review
- URL: https://www.fdaweb.com/merck-scraps-nemtabrutinib-development-after-risk-benefit-review/
- Published: 2026-11-18T20:03:38.000Z
- Updated: 2026-11-18T20:03:38.000Z
- Author: David McFarland
- Tags: Drugs

Merck has discontinued its entire BELLWAVE clinical development program evaluating nemtabrutinib (MK-1026), an investigational oral Bruton's tyrosine kinase (BTK) inhibitor for chronic lymphocytic leukemia, small lymphocytic leukemia, and other blood cancers, following concerns that the drug's benefits may not outweigh its risks.

The company said an external Data Monitoring Committee reviewing the Phase 3 BELLWAVE-011 trial ([NCT06136559](https://clinicaltrials.gov/study/NCT06136559?ref=fdaweb.com)) identified an unfavorable potential risk-benefit profile. Merck subsequently confirmed the assessment after reviewing available data.

The decision also ends two additional Phase 3 studies, BELLWAVE-008 ([NCT05624554](https://clinicaltrials.gov/study/NCT05624554?ref=fdaweb.com)) and BELLWAVE-010 ([NCT05947851](https://clinicaltrials.gov/study/NCT05947851?ref=fdaweb.com)).

Merck did not disclose specific safety concerns or efficacy findings underlying the decision.

The company said it is notifying investigators and advising participating patients to consult their physicians about treatment options. Analyses of the trial data are continuing, with results expected to be shared with the scientific community.